Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Scholz

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
The Prostate|December 24, 2002
Using splines to detect changes in PSA doubling timesBrad Guess, Robert Jennrich, Henry Johnson, et al.
Urology|October 2, 2007
Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticalsMark Scholz, Richard Lam, Stephen Strum, et al.
Clinical Genitourinary Cancer|January 11, 2020
Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate CancerJulianna Higa, Kirk Wilenius, Shannon Savino, et al.
The Journal of Urology|May 10, 2005
Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisoneMark Scholz, Robert Jennrich, Stephen Strum, et al.
Archives of Surgery (Chicago, Ill. : 1960)|March 22, 2006
Perioperative morbidity associated with bariatric surgery: an academic center experienceRobert W O'Rourke, Jason Andrus, Brian S Diggs, et al.
Immunotargets and Therapy|April 1, 2017
Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancerMark Scholz, Sabrina Yep, Micah Chancey, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-TTanya Dorff, Yosuke Hirasawa, Jared Acoba, et al.
Journal for Immunotherapy of Cancer|February 4, 2022
Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapyJoanne Weidhaas, Nicholas Marco, Aaron W Scheffler, et al.
The Prostate|February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North AmericaAnthony M Joshua, Neal D Shore, Fred Saad, et al.
BJU International|January 14, 2012
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupPeter Grimm, Ignace Billiet, David Bostwick, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The Prostate|December 24, 2002
Using splines to detect changes in PSA doubling timesBrad Guess, Robert Jennrich, Henry Johnson, et al.
Urology|October 2, 2007
Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticalsMark Scholz, Richard Lam, Stephen Strum, et al.
Clinical Genitourinary Cancer|January 11, 2020
Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate CancerJulianna Higa, Kirk Wilenius, Shannon Savino, et al.
The Journal of Urology|May 10, 2005
Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisoneMark Scholz, Robert Jennrich, Stephen Strum, et al.
Archives of Surgery (Chicago, Ill. : 1960)|March 22, 2006
Perioperative morbidity associated with bariatric surgery: an academic center experienceRobert W O'Rourke, Jason Andrus, Brian S Diggs, et al.
Immunotargets and Therapy|April 1, 2017
Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancerMark Scholz, Sabrina Yep, Micah Chancey, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-TTanya Dorff, Yosuke Hirasawa, Jared Acoba, et al.
Journal for Immunotherapy of Cancer|February 4, 2022
Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapyJoanne Weidhaas, Nicholas Marco, Aaron W Scheffler, et al.
The Prostate|February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North AmericaAnthony M Joshua, Neal D Shore, Fred Saad, et al.
BJU International|January 14, 2012
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupPeter Grimm, Ignace Billiet, David Bostwick, et al.
Pageof 2